Sign In
Buy BIO
$304.83
-1.30 (-0.425%)
At Close: Jun 03, 2026
Bio-Rad (BIO) Q2 Earnings Surpass Estimates, Gross Margin Up
03:28pm, Friday, 29'th Jul 2022 Zacks Investment Research
Overall demand for Bio-Rad's (BIO) Life Science and Clinical Diagnostics continues to be strong on localized surges of COVID-19.
Bio-Rad (BIO) Q2 Earnings Surpass Estimates, Gross Margin Up
02:02pm, Friday, 29'th Jul 2022
Overall demand for Bio-Rad's (BIO) Life Science and Clinical Diagnostics continues to be strong on localized surges of COVID-19.
Bio-Rad Laboratories, Inc. (BIO) Management on Q2 2022 Results - Earnings Call Transcript
09:52pm, Thursday, 28'th Jul 2022
Bio-Rad Laboratories, Inc. (NYSE:BIO ) Q2 2022 Earnings Conference Call July 28, 2022 6:00 PM ET Company Participants Edward Chung - Head of Investor Relations Ilan Daskal - Executive Vice President &
Bio-Rad Laboratories (BIO) Surpasses Q2 Earnings and Revenue Estimates
09:45pm, Thursday, 28'th Jul 2022 Zacks Investment Research
Bio-Rad (BIO) delivered earnings and revenue surprises of 37.40% and 3.94%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Bio-Rad Laboratories (BIO) Surpasses Q2 Earnings and Revenue Estimates
07:30pm, Thursday, 28'th Jul 2022
Bio-Rad (BIO) delivered earnings and revenue surprises of 37.40% and 3.94%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Medical Device Stocks to Watch for Earnings on Jul 28
04:05pm, Wednesday, 27'th Jul 2022 Zacks Investment Research
Medical Device players are likely to have benefited from the reopening of economies and several efforts to combat staffing challenges. Let's see how LH, TMO and BIO will likely fare this time.
Bio-Rad (BIO) to Report Q2 Earnings: What's in the Cards?
01:49pm, Friday, 22'nd Jul 2022 Zacks Investment Research
Bio-Rad's (BIO) Clinical Diagnostics segment is expected to report growth in Q2, driven by its focus on laboratory workflow productivity, quality control, and new opportunities in molecular diagnostic
Tesla, Danaher And Some Other Big Gainers From Yesterday
09:40am, Friday, 22'nd Jul 2022 Benzinga
U.S. stocks closed higher on Thursday, with the Nasdaq Composite jumping around 1.4%. Here is the list of some big stocks recording gains in the previous session.
Tabula Rasa HealthCare, Inc. (NASDAQ
This Healthcare Stock Jumped 110%; Here Are 64 Biggest Movers From Yesterday
09:04am, Friday, 22'nd Jul 2022 Benzinga
Gainers
Virax Biolabs Group Limited (NASDAQ: VRAX) shares climbed 264% to close at $18.20 on Thursday. The company offered shares at an expected price of $5.00 per share with an insider lock-up peri
Why Is Super Micro Computer Higher By More Than 13%? 42 Stocks Moving In Thursday's Mid-Day Session
04:33pm, Thursday, 21'st Jul 2022 Benzinga
Gainers
Virax Biolabs Group Limited (NASDAQ: VRAX) shares jumped 364.3% to $23.22. The company offered shares at an expected price of $5.00 per share with an insider lock-up period of 180 days endin
Bio-Rad to Report Second Quarter 2022 Financial Results on Thursday, July 28, 2022
04:15pm, Monday, 18'th Jul 2022
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, will report its financial results for the
Here's Why You Should Invest in Bio-Rad (BIO) Stock Now
04:38pm, Friday, 17'th Jun 2022 Zacks Investment Research
Investors are optimistic about Bio-Rad's (BIO) strong growth in its key product lines across several geographies.
Here's Why You Should Invest in Bio-Rad (BIO) Stock Now
01:55pm, Friday, 17'th Jun 2022
Investors are optimistic about Bio-Rad's (BIO) strong growth in its key product lines across several geographies.
What's in Store for Patterson Companies' (PDCO) Q4 Earnings?
01:47pm, Thursday, 16'th Jun 2022 Zacks Investment Research
Patterson Companies' (PDCO) fiscal fourth-quarter results are likely to reflect improvement at the Animal Health segment.
Bio-Rad (BIO) Immunohematology Arm Recovers, New Launches Aid
03:03pm, Monday, 06'th Jun 2022 Zacks Investment Research
Bio-Rad's (BIO) qPCR business is experiencing excellent uptake from the new-generation CFX Opus platform.
